Evotec AG (NASDAQ:EVO) Receives Consensus Rating of “Hold” from Brokerages

Shares of Evotec AG (NASDAQ:EVO) have earned a consensus rating of “Hold” from the five research firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $7.00.

Several research analysts have commented on the stock. Wall Street Zen upgraded shares of Evotec from a “sell” rating to a “hold” rating in a report on Saturday, January 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Evotec in a research report on Monday, December 29th. Finally, Berenberg Bank assumed coverage on shares of Evotec in a report on Tuesday, February 3rd. They issued a “buy” rating for the company.

Institutional Investors Weigh In On Evotec

Several hedge funds have recently made changes to their positions in the company. Marshall Wace LLP purchased a new stake in Evotec in the fourth quarter worth $40,000. Valeo Financial Advisors LLC bought a new stake in shares of Evotec during the 2nd quarter valued at $43,000. BNP Paribas Financial Markets grew its position in shares of Evotec by 62.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock worth $50,000 after buying an additional 4,600 shares during the period. Bank of America Corp DE increased its stake in shares of Evotec by 262.5% in the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after acquiring an additional 9,289 shares in the last quarter. Finally, Thrivent Financial for Lutherans purchased a new position in Evotec during the 3rd quarter valued at about $53,000. 5.81% of the stock is currently owned by institutional investors.

Evotec Trading Down 0.3%

Shares of Evotec stock opened at $3.40 on Friday. The business has a 50 day moving average of $3.47 and a 200 day moving average of $3.50. Evotec has a 52 week low of $2.84 and a 52 week high of $4.80. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.03 and a current ratio of 2.12.

Evotec Company Profile

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.